ClinicalTrials.gg
CompletedNCT07158437Updated Nov 17, 2026

Phase 1 Study of SL-325 in Healthy Volunteers

A Phase 1 interventional study of SL-325 and Placebo (Normal Saline) in Healthy Volunteers, sponsored by Shattuck Labs, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shattuck Labs, Inc. · Phase 1, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • DR3
  • SL-325
03

In context

Lead sponsor

Shattuck Labs, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide signed
  2. 18-55 years of age, inclusive, at the time of signing the informed consent form
  3. of 18-32 kg/m2, inclusive, and a total body weight > 50 kg
  4. Laboratory values within normal limits or any abnormalities deemed not by the Investigator
  5. Participant agrees to practice measures

Exclusion criteria

Exclusion Criteria:

  1. History or presence of a infectious disease or hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, neurologic, or psychiatric abnormality
  2. Any clinically significant abnormality on vital signs, (ECG), or laboratory parameters
  3. History of regular alcohol consumption within 6 months of Screening
  4. Positive test for use of drugs or alcohol at Screening
  5. History of use of tobacco- or nicotine-containing products within 3 months of Screening
  6. History of infusion-related reaction or allergic reaction upon receipt of an IV infusion
  7. Positive virus, virus, or (HIV) test at Screening
  8. Blood donation within 90 days prior to Day -1 or plasma donation within 1 week prior to Day 1
  9. Receipt of specific medications within a specified time period
  10. Women who are currently breastfeeding or have a positive pregnancy test
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    SAD: SL-325

    Participants will receive a single dose of SL-325 in escalating dose cohorts

    Biological: SL-325

  • Placebo comparator
    SAD: Placebo

    Participants will receive a single dose of placebo (normal saline)

    Other: Placebo (Normal Saline)

  • Experimental
    MAD: SL-325

    Participants will receive a three doses of SL-325 in escalating dose cohorts

    Biological: SL-325

  • Placebo comparator
    MAD: Placebo

    Participants will receive a three doses of placebo (normal saline)

    Other: Placebo (Normal Saline)

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Incidence and severity of treatment-emergent adverse events

    Time frame: Day 1 through 75 days after last dose

Secondary outcomes

  1. Pharmacokinetics (PK): Cmax

    Maximum observed concentration

    Time frame: Day 1 through 75 days after last dose

  2. Pharmacokinetics (PK): Tmax

    Time at which the maximum concentration is observed

    Time frame: Day 1 through 75 days after last dose

  3. Pharmacokinetics (PK): Ctrough

    Minimum observed concentration following a single dose

    Time frame: Day 1 through 75 days after last dose

  4. Pharmacokinetics (PK): AUC

    Area under the concentration-time curve

    Time frame: Day 1 through 75 days after last dose

  5. Pharmacokinetics (PK): T1/2

    Terminal elimination half-life

    Time frame: Day 1 through 75 days after last dose

  6. Pharmacokinetics (PK): CL

    Clearance

    Time frame: Day 1 through 75 days after last dose

  7. Pharmacokinetics (PK): Vz

    Volume of distribution

    Time frame: Day 1 through 75 days after last dose

  8. Immunogenicity: Number/proportion of participants with positive or negative anti-drug antibody (ADA) titers

    Time frame: Day 1 through 75 days after last dose

  9. Immunogenicity: Number/proportion of participants with neutralizing anti-drug antibodies

    Time frame: Day 1 through 75 days after last dose

  10. Immunogenicity: Time to onset and duration of anti-drug antibodies

    Time frame: Day 1 through 75 days after last dose

  11. Immunogenicity: Number/proportion of participants with transient vs persistent anti-drug antibodies

    Time frame: Day 1 through 75 days after last dose

  12. Receptor Occupancy: Percent of DR3-positive T cells bound by SL-325

    Time frame: Day 1 through 75 days after last dose

  13. Receptor Occupancy: Duration of DR3-positive T cell binding by SL-325

    Time frame: Day 1 through 75 days after last dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Jul 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartActual
Sep 18, 2025
Primary completionActual
Jul 16, 2026
CompletionActual
Jul 16, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07158437
Lead sponsor
Shattuck Labs, Inc.
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Sep 18, 2025
Primary completion
Jul 16, 2026
Completion
Jul 16, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 3-(2-(4-quinolin-3-yl)benzyl-1-oxoisoindolin-6-yl)-N-hydroxy-acrylamide

Start the discussion